Shots:
- Mabwell has signed licensing and commercialization agreements with local partners in the Philippines, Vietnam, and Malaysia for its aflibercept biosimilar, a biosimilar version of Eylea
- As per the deal, Mabwell and its partners jointly advance the product’s registration and commercialization in these markets
- Aflibercept is a VEGF inhibitor approved for the treatment of Neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, DME, & diabetic retinopathy
Ref: Mabwell | Image: Mabwell | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
